Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor–resistant <i>NRAS</i> -mutant melanomaBrittany C. Lipchick(The Wistar Institute), Jessie Villanueva(The Wistar Institute)Science Translational MedicineFebruary 5, 202510.1126/scitranslmed.adp8913Cited by 4SaveCiteExport RISWatch citationsRelated PapersExploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma|Oncogene|2018|54